Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

Y0001595

Diacerein

European Pharmacopoeia (EP) Reference Standard

Synonym(e):

1,8-Diacetoxy-3-carboxyanthrachinon

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C19H12O8
CAS-Nummer:
13739-02-1
Molekulargewicht:
368.29
MDL-Nummer:
MFCD00468030
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329831501
NACRES:
NA.24
Preise und Verfügbarkeit sind derzeit nicht verfügbar.

Qualität

pharmaceutical primary standard

API-Familie

diacerein

Hersteller/Markenname

EDQM

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

SMILES String

CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O

InChI

1S/C19H12O8/c1-8(20)26-13-5-3-4-11-15(13)18(23)16-12(17(11)22)6-10(19(24)25)7-14(16)27-9(2)21/h3-7H,1-2H3,(H,24,25)

InChIKey

TYNLGDBUJLVSMA-UHFFFAOYSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Verwandte Kategorien

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 4

Dieser Artikel
D9302Y0001597D2953000
Diacerein European Pharmacopoeia (EP) Reference Standard

Y0001595

Diacerein

Diacerein ≥95% (HPLC)

D9302

Diacerein

vibrant-m

Y0001597

Diacerein Unreinheit (gemischt)

Dithranol European Pharmacopoeia (EP) Reference Standard

D2953000

Dithranol

grade

pharmaceutical primary standard

grade

-

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

format

neat

format

-

format

neat

format

neat

application(s)

pharmaceutical (small molecule)

application(s)

-

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

API family

diacerein

API family

-

API family

diacerein

API family

anthralin, dithranol

storage temp.

2-8°C

storage temp.

-

storage temp.

−20°C

storage temp.

2-8°C

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Diacerein EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Verpackung

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

Piktogramme

Exclamation mark
GHS07

Signalwort

Warning

Gefahreneinstufungen

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Zielorgane

Respiratory system

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

N G de Isla et al.
Bio-medical materials and engineering, 18(1 Suppl), S99-104 (2008-05-06)
Osteoarthritis (OA) is a progressive joint disease which represents a combination of several disorders leading to cartilage degradation. The production of nitric oxide (NO) by iNOS, which is stimulated by proinflammatory mediators, is involved in cartilage catabolism and should therefore
Marie Solignac
Presse medicale (Paris, France : 1983), 33(9 Pt 2), S10-S12 (2004-07-01)
DEGRADATION AND REPAIR: Osteoarthritis generally occurs in a context of an overloaded normal cartilage matrix or normal loading of a vulnerable cartilage matrix. Interleukin-1 appears to be principally indicated in degradation phenomena while transforming growth factor (TGFbeta) is mainly implicated
[Diacerein].
G Passiu
Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna, 1(2), 172-174 (1986-06-01)
G Falgarone et al.
Current rheumatology reports, 3(6), 479-483 (2001-11-16)
This paper reviews the most recent clinical and experimental studies on diacerein, both of which are under investigation. Diacerein could be a disease-modulating agent in osteoarthritis because structural benefits have been reported in recent trials. Moreover, after an empirical use
T S A Fidelix et al.
The Cochrane database of systematic reviews, (1)(1), CD005117-CD005117 (2006-01-27)
Osteoarthritis (OA) is one of the most prevalent musculoskeletal diseases. Diacerein acts differently from traditional non-steroidal anti-inflammatory drugs (NSAIDs) which inhibit prostaglandin synthesis, leading to adverse gastrointestinal effects. It has been proposed that diacerein acts as a slow-acting, symptom-modifying and
Alle zugehörigen Dokumente anzeigen

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.